{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chemonaive", "query": { "condition": "Chemonaive" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 11, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chemonaive&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T01:00:09.749Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00533429", "title": "Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Participants With Non-Small Cell Lung Cancer Who Have Not Been Previously Treated With Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "enzastaurin", "type": "DRUG" }, { "name": "pemetrexed", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "bevacizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2007-10", "completion_date": "2009-02", "has_results": true, "last_update_posted_date": "2021-05-13", "last_synced_at": "2026-05-22T01:00:09.749Z", "location_count": 12, "location_summary": "Bentonville, Arkansas • Chicago, Illinois • Galesburg, Illinois + 9 more", "locations": [ { "city": "Bentonville", "state": "Arkansas" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Galesburg", "state": "Illinois" }, { "city": "Bloomington", "state": "Indiana" }, { "city": "Evansville", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00533429" }, { "nct_id": "NCT00856830", "title": "Bendamustine With Irinotecan Followed by Etoposide/Carboplatin for Patients With Extensive Stage Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Small Cell Lung Cancer", "Extensive Stage Lung Cancer", "Chemonaive" ], "interventions": [ { "name": "Novel Drug Combination", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 30, "start_date": "2009-04", "completion_date": "2016-05", "has_results": true, "last_update_posted_date": "2017-07-17", "last_synced_at": "2026-05-22T01:00:09.749Z", "location_count": 2, "location_summary": "Birmingham, Alabama • Marietta, Georgia", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Marietta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00856830" }, { "nct_id": "NCT00113256", "title": "Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "Rubitecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astex Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2005-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2024-08-02", "last_synced_at": "2026-05-22T01:00:09.749Z", "location_count": 11, "location_summary": "Corona, California • Fountain Valley, California • Soquel, California + 7 more", "locations": [ { "city": "Corona", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Soquel", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT00113256" }, { "nct_id": "NCT00316186", "title": "First-line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer With Weekly Hycamtin And Paraplatin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer, Small Cell" ], "interventions": [ { "name": "topotecan", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2005-06", "completion_date": "2009-05", "has_results": true, "last_update_posted_date": "2015-05-07", "last_synced_at": "2026-05-22T01:00:09.749Z", "location_count": 12, "location_summary": "Tucson, Arizona • Concord, California • Sacramento, California + 9 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Concord", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Hollywood", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00316186" }, { "nct_id": "NCT01042522", "title": "Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Granulosa Cell Tumor", "Ovarian Gynandroblastoma", "Ovarian Sertoli-Leydig Cell Tumor", "Ovarian Sex Cord Tumor With Annular Tubules", "Ovarian Sex Cord-Stromal Tumor", "Ovarian Sex Cord-Stromal Tumor, Not Otherwise Specified", "Ovarian Steroid Cell Tumor" ], "interventions": [ { "name": "Bleomycin Sulfate", "type": "BIOLOGICAL" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Etoposide Phosphate", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "GOG Foundation", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 63, "start_date": "2010-02-08", "completion_date": "2022-11-02", "has_results": true, "last_update_posted_date": "2022-01-25", "last_synced_at": "2026-05-22T01:00:09.749Z", "location_count": 219, "location_summary": "Anchorage, Alaska • Burbank, California • Sylmar, California + 156 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01042522" }, { "nct_id": "NCT01064648", "title": "Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Epithelioid Mesothelioma", "Pleural Malignant Mesothelioma", "Recurrent Malignant Mesothelioma", "Sarcomatoid Mesothelioma" ], "interventions": [ { "name": "Cediranib Maleate", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pemetrexed Disodium", "type": "DRUG" }, { "name": "Placebo Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 117, "start_date": "2010-03-15", "completion_date": "2027-03-31", "has_results": true, "last_update_posted_date": "2026-04-29", "last_synced_at": "2026-05-22T01:00:09.749Z", "location_count": 231, "location_summary": "Rogers, Arkansas • Antioch, California • Burbank, California + 149 more", "locations": [ { "city": "Rogers", "state": "Arkansas" }, { "city": "Antioch", "state": "California" }, { "city": "Burbank", "state": "California" }, { "city": "Fremont", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01064648" }, { "nct_id": "NCT01221077", "title": "Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "NSCLC", "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "OSI-906", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 88, "start_date": "2011-04-08", "completion_date": "2014-09-01", "has_results": false, "last_update_posted_date": "2025-11-18", "last_synced_at": "2026-05-22T01:00:09.749Z", "location_count": 13, "location_summary": "La Jolla, California • Tampa, Florida • Weston, Florida + 8 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Weston", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01221077" }, { "nct_id": "NCT00005869", "title": "Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "rubitecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astex Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1998-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-12-04", "last_synced_at": "2026-05-22T01:00:09.749Z", "location_count": 1, "location_summary": "Dublin, California", "locations": [ { "city": "Dublin", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005869" }, { "nct_id": "NCT01409174", "title": "IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Interferon Alfa-2b", "type": "DRUG" }, { "name": "Interleukin-2", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 19, "start_date": "2013-02", "completion_date": "2016-05", "has_results": false, "last_update_posted_date": "2017-05-31", "last_synced_at": "2026-05-22T01:00:09.749Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01409174" }, { "nct_id": "NCT00300885", "title": "A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Non-Small Cell Lung" ], "interventions": [ { "name": "Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel", "type": "DRUG" }, { "name": "Carboplatin plus Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 926, "start_date": "2006-02", "completion_date": "2009-02", "has_results": true, "last_update_posted_date": "2014-11-04", "last_synced_at": "2026-05-22T01:00:09.749Z", "location_count": 80, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 69 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00300885" } ] }